One in Nine US Adults Now Takes a GLP-1 — and the Obesity Rate Is Falling

The figures

Gallup National Health and Well-Being Index, 5,065 adults surveyed 28 May to 5 June 2026. Obesity prevalence from separate national measurement.

Adoption at this scale is genuinely unusual in pharmacotherapy. Very few medication classes reach one in nine adults for a single indication, and none has done so this quickly in recent memory.

What this establishes, and what it does not

A population-level correlation between rising treatment and falling prevalence. That is suggestive and not conclusive: the measures come from independent datasets, medication use is self-reported, and obesity prevalence moves for many reasons that have nothing to do with any drug.

What can be said more confidently is that adoption has outpaced the accumulation of long-term evidence. The longest published controlled follow-up in this field is the three-year SURMOUNT-1 prediabetes analysis. Millions of people are taking these drugs on an open-ended basis with roughly three years of controlled data behind that decision.

That is not an argument against them. It is context for how much confidence any long-horizon claim about this class deserves — in either direction.

The gap inside the numbers

Fifteen per cent report ever-use and 11% report current use. That four-point gap represents people who started and stopped — millions of them, and it is the least-discussed figure in the survey.

Some stopped because of side effects; SURMOUNT-1 recorded 4.3% to 7.1% discontinuation for adverse events depending on dose. Some stopped because of cost. Some because supply changed, or coverage lapsed, or a prepaid plan ended. The survey does not separate them, and no published dataset does it well.

Why adoption accelerated when it did

Three barriers fell within eighteen months, and each removed a different constraint.

Oral options arrived. The Wegovy pill launched in January 2026 and reportedly passed three million prescriptions within about five months; Foundayo followed in April. Needle avoidance was a real barrier rather than a stated preference, and the uptake rate suggests it was suppressing demand independently of price.

Brand prices fell sharply. Zepbound is now $299 to $449 direct from LillyDirect, and both approved oral GLP-1s start at $149. Eighteen months ago list prices above $1,000 were the reference point that made the compounded market inevitable.

Medicare opened a door. The GLP-1 Bridge began 1 July 2026 at a flat $50 copay for eligible Part D enrollees, the first time Medicare has covered these drugs for weight loss. Federal law otherwise excludes them.

What it means for the market you are shopping in

Scale changes competitive dynamics. A category serving 40 million people attracts more entrants, more price competition, and more marketing of variable quality — which is why the volume of comparison content in this space has grown faster than the quality of it.

It also changes the regulatory picture. The FDA's proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list is a decision about a market this large, which is part of why it has been contested at every step.

What it should not change about your decision

Scale is not evidence of appropriateness. Forty million users tells you the market moved. It does not tell you whether this suits your history, your tolerability or your circumstances, and it does not shorten the list of questions worth asking a clinician first.

The boxed warning for thyroid C-cell tumours applies whether one person or forty million are taking the drug. So do the contraindications, and so does the evidence that stopping is followed by substantial regain.

What this costs, and where the money actually goes

Whatever the clinical question on this page, the financial one behind it is the same for almost every reader: this is an indefinite treatment, and the figure that matters is the monthly cost at a maintenance dose rather than the advertised entry price.

The Zepbound label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage. Recommended maintenance dosages are 5, 10 and 15 mg, and increases are directed no sooner than every four weeks based on tolerability and response. So an advertised entry price describes roughly four weeks of a treatment most people take for years, and comparing providers on it compares them on a price nobody pays after month one.

Coverage beats every self-pay route by an order of magnitude. Establishing whether you qualify takes one phone call and is worth more than any price comparison.

Three mechanisms separate an advertised figure from what you pay. A required membership, which runs from $19.99 to $149 a month across the providers we track. Dose-escalation pricing, where the monthly cost rises as you titrate. And introductory rates, which apply to one month of an indefinite course — eleven programmes advertise one, and all are excluded from every ranking we publish.

The single question that resolves most of this is what you will pay at 10 mg, including every required fee. A provider who answers that plainly can be compared accurately, which is generally to the advantage of providers with nothing to hide.

How to check any claim on this page for yourself

Everything above should be checkable, and most of it is. Trial claims resolve to a registry entry and a peer-reviewed publication; regulatory claims resolve to an agency document; pricing claims resolve to a provider’s own published page read on a stated date.

Where we could not verify something, we say so rather than rounding it into confidence. Every pharmacy relationship on this site carries a reported rather than verified label, because not one provider has named its fulfilling pharmacy and registration class to us. That is the field we would weight most heavily if we had it, and it is the question worth putting first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.

Four checks take about ten minutes between them. Confirm your prescriber holds a current licence in your state, through that state’s medical board rather than through the provider’s own page. Confirm the fulfilling pharmacy is licensed, and registered as a nonresident pharmacy in your state if it ships from elsewhere. Search the pharmacy’s name against FDA warning letters and recall notices, both public. And ask for a certificate of analysis matched to the batch number on your vial.

None of that establishes that the medicine in your hand is safe. It establishes that the parties involved are inside the regulatory system and currently authorised, which is a floor rather than a guarantee. The honest framing is that you are reducing risk rather than eliminating it — and a provider unwilling to give you the names needed to run those checks has told you something worth knowing.